Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at https://www.facebook.com/jamescgreenwood.

Latest Posts

Bill Gates is Right

new-bio-logo

In a recent Bloomberg interview, Microsoft founder and noted philanthropist Bill Gates debunked much of the recent criticism of the biopharmaceutical industry and the drug pricing system in the United States, stating: “The current system is better than most other systems one can imagine … The drug companies are turning out miracles, and we need their R&D budgets to stay strong. They need to see the opportunity.” Gates also praised the innovations that are coming Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,

Bloomberg Caught Spreading Another Inaccurate “False Alarm” About Drug Prices

Greenwood_Jim_BTN

I was deeply disturbed by Bloomberg’s inaccurate report this morning that attempted to examine drug costs. The article claims it “decodes [our industry’s]…pricing practices.” But, in reality, it does no such thing. It fails to take in the full picture of biopharmaceutical successes and failures; admits its “proof” is merely guesstimates from an organization that wasn’t involved in pricing decisions; and in some cases, it just plain gets the facts wrong. First, this article myopically Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Stop Demeaning the Healthy Dialogue Between Doctors and Drug Companies

Greenwood_Jim_BTN

A recent report in The Wall Street Journal entitled, “Even Cheap Meals Influence Doctors’ Drug Prescriptions, Study Suggests,” attempts to suggest an untoward influence resulting from drug company-sponsored physician education events. After reading the full study, it is clear that the WSJ author not only misinterpreted the conclusions of the study, but completely discounts the role that companies have in educating physicians about their products. Contrary to the author’s point, communication between drug companies and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Time for AHIP to Finally Join Us And Work Toward A Solution

Greenwood_Jim_BTN

I worked as an elected leader in government for 24 years. One of the enduring lessons I learned is that to accomplish big things, people from different backgrounds must come together and unite behind a common solution. When that happens, our nation flourishes. And those problems that once seemed deep and complex, suddenly don’t seem so insurmountable anymore. That’s why it was so disappointing to hear America’s Health Insurance Plans’ (AHIP) ridiculous claim that my Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

ICER’s Flawed Methodology Could Lead To Healthcare Rationing

Greenwood_Jim_BTN

In a column published in USA Today recently, Jeff Stier, a Senior Fellow at the National Center for Public Policy Research, sheds light on the Institute for Clinical and Economic Review (ICER). Stier points out the group’s fundamentally-flawed (and possibly dangerous) approach and how their reports influence which drugs are listed on your insurer’s formulary based on what those drugs will cost the insurer – rather than what’s best for you as a patient.  “…we’ve Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,